酮己糖激酶抑制剂PF-06835919对OATP1B体内活性的影响:基于内源性生物标志物与探针药物的整合风险评估
本研究在健康受试者中评估KHKi(PF-06835919)对OATP1B体内活性的剂量依赖性影响。采用开放标签设计,比较阿托伐他汀单用与联用KHKi(50和280 mg每日一次)的药代动力学,并检测内源性标志物CP-I。结果显示高剂量KHKi使阿托伐他汀AUC几何均值比为1.54(1.37-1.74),CP-I暴露呈剂量依赖性升高,PBPK模型预测OATP1B抑制程度随剂量增加。
要点
- KHKi 280 mg每日一次使阿托伐他汀AUC几何均值比升至1.54(1.37-1.74)。
- CP-I暴露在50和280 mg KHKi下分别升高1.12倍和1.49倍(AUC)。
- PBPK模型预测100-600 mg剂量范围内OATP1B抑制程度约13%至70%。
核心结论
- KHKi对OATP1B体内活性具有剂量依赖性抑制作用,高剂量时产生弱效DDI风险。
研究设计与样本
- 开放标签研究,12名健康受试者比较阿托伐他汀单用与联用KHKi(50和280 mg每日一次)的药代动力学。
- 另设单次口服KHKi(100-600 mg)研究,6名健康受试者评估CP-I暴露变化。
主要发现
- 阿托伐他汀AUC几何均值比(90%CI)在50 mg和280 mg KHKi下分别为1.14(1.00-1.30)和1.54(1.37-1.74)。
- CP-I的AUC在50和280 mg KHKi下分别升高1.12倍和1.49倍;单次给药100-600 mg下最高升高1.80倍。
- PBPK模型基于体外抑制效力(1.9 µM)预测100-600 mg剂量范围内OATP1B抑制程度约13%至70%。
- 模型分析正确预测低剂量范围无效应(AUC比<1.25)和高剂量范围弱效应(AUC比<2)。
临床怎么用
- 临床联用KHKi高剂量(280 mg每日一次)时需关注OATP1B底物药物(如阿托伐他汀)的暴露增加。
- 可利用CP-I作为内源性生物标志物辅助评估OATP1B介导的DDI风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PF-06835919 is a first-in-class ketohexokinase inhibitor (KHKi), recently under development for the treatment of metabolic and fatty liver diseases, which inhibited organic anion transporting polypeptide (OATP)1B1 in vitro and presented drug-drug interaction (DDI) risk. This study aims to investigate the dose-dependent effect of KHKi on OATP1B in vivo activity. We performed an open-label study comparing pharmacokinetics of atorvastatin (OATP1B probe) dosed alone (20 mg single dose) and coadministered with two dose strengths of KHKi (50 and 280 mg once daily) in 12 healthy participants. Additionally, changes in exposure of coproporphyrin-I (CP-I), an endogenous biomarker for OATP1B, were assessed in the atorvastatin study (1.12-fold and 1.49-fold increase in area under the plasma concentration-time profile (AUC) with once-daily 50 and 280 mg, respectively), and a separate single oral dose study of KHKi alone (100-600 mg, n = 6 healthy participants; up to a 1.80-fold increase in AUC). Geometric mean ratios (90% confidence interval) of atorvastatin AUC following 50 and 280 mg KHKi were 1.14 (1.00-1.30) and 1.54 (1.37-1.74), respectively. Physiologically-based pharmacokinetic modeling of CP-I plasma exposure following a single dose of KHKi predicted in vivo OATP1B inhibition from about 13% to 70% over the 100 to 600 mg dose range, while using the in vitro inhibition potency (1.9 µM). Model-based analysis correctly predicted "no-effect" (AUC ratio < 1.25) at the low dose range and "weak" effect (AUC ratio < 2) on atorvastatin pharmacokinetics at the high dose range of KHKi. This study exemplified the utility of biomarker-informed model-based approach in discerning even small effects on OATP1B activity in vivo, and to project DDI risk at the clinically relevant doses.
引用
- Tess DA, Kimoto E, King-Ahmad A, et al. Effect of a Ketohexokinase Inhibitor (PF-06835919) on In Vivo OATP1B Activity: Integrative Risk Assessment Using Endogenous Biomarker and a Probe Drug. Clin Pharmacol Ther. 2022. PMID: 35355249. doi:10.1002/cpt.2593
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。